The funding seeks to establish preclinical and clinical proof of concept for a vaccine designed to provide protection against all known SARS-CoV-2 variants.
CEPI will fund the researchers to conduct activities including immunogen design, preclinical studies, manufacturing process development and a Phase 1 clinical trial.
It will fund the researchers to conduct activities including immunogen design, preclinical studies, and a Phase 1 clinical trial. In this, modified immunogens will be produced in a scalable process with high purity and yield at a low cost.
The Coalition for Epidemic Preparedness Innovations (CEPI) on Tuesday announced the latest award under its USD 200 m programme to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other beta coronaviruses.
The Coalition for Epidemic Preparedness Innovations (CEPI) on Tuesday announced the latest award under its USD 200 m programme to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other beta coronaviruses. Bharat Biotech Consortium Gets $19 Million Funding For Development of Variant Proof COVID-19 Vaccine.